Technical Analysis for ACST - Acasti Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Historical ACST trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
New Uptrend | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
New Downtrend | Bearish | 13.02% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 13.02% | |
Wide Bands | Range Expansion | 13.02% | |
Gapped Down | Weakness | 13.02% | |
Fell Below 20 DMA | Bearish | -0.48% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -0.48% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.48% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
20 DMA Resistance | about 18 hours ago | |
Rose Above 20 DMA | about 18 hours ago | |
60 Minute Opening Range Breakout | about 18 hours ago | |
Up 1 ATR | about 18 hours ago | |
Non-ADX 1,2,3,4 Pullback Entry | about 20 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cardiovascular Disease Lipid Drug Product Metabolic Disorders Fatty Acids Lipids Triglyceride Medical Food Cardiovascular Disorders Hypertriglyceridemia Omega 3 Fatty Acid Onemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cardiovascular Disease Lipid Drug Product Metabolic Disorders Fatty Acids Lipids Triglyceride Medical Food Cardiovascular Disorders Hypertriglyceridemia Omega 3 Fatty Acid Onemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.22 |
52 Week Low | 0.171 |
Average Volume | 59,972,193 |
200-Day Moving Average | 0.51 |
50-Day Moving Average | 0.63 |
20-Day Moving Average | 0.86 |
10-Day Moving Average | 0.97 |
Average True Range | 0.13 |
ADX | 46.32 |
+DI | 33.55 |
-DI | 27.05 |
Chandelier Exit (Long, 3 ATRs ) | 0.83 |
Chandelier Exit (Short, 3 ATRs ) | 0.96 |
Upper Bollinger Band | 1.19 |
Lower Bollinger Band | 0.53 |
Percent B (%b) | 0.46 |
BandWidth | 76.73 |
MACD Line | 0.07 |
MACD Signal Line | 0.10 |
MACD Histogram | -0.0341 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.04 | ||||
Resistance 3 (R3) | 1.04 | 0.97 | 1.01 | ||
Resistance 2 (R2) | 0.97 | 0.92 | 0.97 | 1.00 | |
Resistance 1 (R1) | 0.90 | 0.89 | 0.94 | 0.90 | 0.98 |
Pivot Point | 0.83 | 0.83 | 0.85 | 0.83 | 0.83 |
Support 1 (S1) | 0.77 | 0.78 | 0.80 | 0.76 | 0.68 |
Support 2 (S2) | 0.70 | 0.75 | 0.70 | 0.67 | |
Support 3 (S3) | 0.63 | 0.70 | 0.66 | ||
Support 4 (S4) | 0.63 |